Global Hemostasis Diagnostics Market Size study & Forecast, by Product (Laboratory Analyzers, Point-of-Care Testing Systems), by Test Type (Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Prothrombin Time Test, Activated Clotting Tim

Global Hemostasis Diagnostics Market Size study & Forecast, by Product (Laboratory Analyzers, Point-of-Care Testing Systems), by Test Type (Activated Partial Thromboplastin Time, D Dimer Test, Fibrinogen Test, Prothrombin Time Test, Activated Clotting Time, Platelet Aggregation Test), by End Use (Hospitals, Diagnostic Centers, Others) and Regional Analysis, 2023-2030

Global Hemostasis Diagnostics Market is valued approximately USD 6.41 million in 2022 and is anticipated to grow with a healthy growth rate of more than 8.60% over the forecast period 2023-2030. Hemostasis diagnostic devices help discover hemostatic disorders that cause excessive bleeding. During hemostasis, blood transforms from liquid to gelatinous. Hemostasis is a technique that the body uses after an injury to limit blood loss and cease blood flow. Following this, there are three further steps: vasoconstriction, platelet plug formation, and blood coagulation. Rising blood clotting diagnostic rates among patients, particularly those who are more prone to losing extra blood from the body after procedures, are important reasons driving market expansion. The growth in the incidence of many diseases such as cancer, diabetes, and neurological disorders, as well as the increase in the older population and lifestyle changes, drive the hemostasis diagnostics market. During the projected period, the worldwide hemostasis diagnostics market is expected to be driven by an increase in the prevalence of haemophilia.

Rising incidents of blood clotting disorders, technical developments in medical treatment, and increased acceptance of automated hemostasis equipment are all having an impact on the growth of the market under consideration. According to the World Bleeding Disorders Registry 2021 report, a survey of 37 countries reported 9,414 people with haemophilia as of December 2021, with South-East Asia having the highest prevalence with 2,828 affected individuals, followed by the Eastern Mediterranean and Africa with 2,418 and 1,027 affected individuals, respectively. Additionally, growing continuous advancement in research and development initiatives to miniaturize molecular and professional diagnostic testing is anticipated to create the lucrative opportunity for the market during forecast period. However, a lack of awareness about hemostasis diseases in developing regions, in addition to stringent government regulations, might hinder the market growth throughout the forecast period of 2023-2030

The key regions considered for the Global Hemostasis Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the widespread use of powerful automated analyzers, the availability of a large patient pool, and the high frequency of blood clot illnesses, and supportive government initiatives. Asia Pacific is expected to grow significantly during the forecast period, the region's rapid market rise can be ascribed to several government efforts aimed at improving health-care infrastructure. The market in the area is expected to grow significantly in comparison to other regions, owing to a change in the base of pharmaceutical businesses and clinical research industries from developed to emerging nations such as China and India.

Major market player included in this report are:
Abbott
Thermo Fisher Scientific Inc.
HORIBA Europe Holding
Medtronic
Technidyne Corporation
Grifols S.A
F. Hoffmann-La Roche Ltd.
NIHON KOHDEN CORPORATION
Haemonetics Corporation
Beckman Coulter Inc.

Recent Developments in the Market:
 In December 2022, the US FDA granted HemoSonics' Quantra Hemostasis System with QStat Cartridge 510(k) commercial approval The QStat Cartridge test, according to the manufacturer, expands Quantra's total diagnostic capabilities. The newest point-of-care hemostasis analyzer in the United States, the next-generation whole-blood hemostasis system, covers the broadest range of clinical purposes.
 In November 2022, a Dutch company, Enzyre, which is developing ambulant diagnostic technology for blood coagulation testing, successfully raised USD 11.9 million (EUR 12 million) in series A funding to help hemophilia patients test from home

Global Hemostasis Diagnostics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Test Type, End Use, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Laboratory Analyzers
Point-of-Care Testing Systems
By Test Type:
Activated Partial Thromboplastin Time
D Dimer Test
Fibrinogen Test
Prothrombin Time Test
Activated Clotting Time
Platelet Aggregation Test
By End Use:
Hospitals
Diagnostic Centers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Abbott
Thermo Fisher Scientific Inc.
HORIBA Europe Holding
Medtronic
Technidyne Corporation
Grifols S.A
F. Hoffmann-La Roche Ltd.
NIHON KOHDEN CORPORATION
Haemonetics Corporation
Beckman Coulter Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.